Growth Factor Therapy and Autologous Lymph Node Transfer in Lymphedema

Trends in Cardiovascular Medicine

Volumn 20, Issue 8, 2010, Pages 249-253

  Hartiala, Pauliina ^a   Saaristo, Anne M ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; HYALURONIC ACID; MESSENGER RNA; METHYLCELLULOSE; NEUROPILIN 1; NEUROPILIN 2; PROTEOHEPARAN SULFATE; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; AUTOTRANSPLANTATION; AXILLARY LYMPH NODE; B LYMPHOCYTE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DENDRITIC CELL; DRUG DELIVERY SYSTEM; HEART VENTRICLE HYPERTROPHY; HUMAN; IMMUNOCYTOTOXICITY; LIPID STORAGE; LIPOSUCTION; LYMPH FLOW; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPH NODE TRANSFER; LYMPHADENECTOMY; LYMPHANGIOGENESIS; LYMPHANGIOGRAPHY; LYMPHATIC DRAINAGE; LYMPHATIC FILARIASIS; LYMPHEDEMA; MASTECTOMY; MORBIDITY; NONHUMAN; PHYSIOTHERAPY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SKIN FIBROSIS; SURGICAL TECHNIQUE; T LYMPHOCYTE;

ANIMALS; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPH NODES; LYMPHANGIOGENESIS; LYMPHATIC SYSTEM; LYMPHEDEMA; TRANSPLANTATION, AUTOLOGOUS;

EID: 84858375066     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2011.11.008     Document Type: Review

References (48)

1. Alitalo K., Tammela T., Petrova T.V. Lymphangiogenesis in development and human disease. Nature 2005, 438:946-953.
2. Baker A., Kim H., Semple J.L., et al. Experimental assessment of pro-lymphangiogenic growth factors in the treatment of post-surgical lymphedema following lymphadenectomy. Breast Cancer Res 2010, 12:R70.
3. Banchereau J., Briere F., Caux C., et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000, 18:767-811.
4. Baumeister R.G., Seifert J., Hahn D. Autotransplantation of lymphatic vessels. Lancet 1981, 1:147.
5. Becker C., Assouad J., Riquet M., Hidden G. Postmastectomy lymphedema: Long-term results following microsurgical lymph node transplantation. Ann Surg 2006, 243:313-315.
6. Blum K.S., Hadamitzky C., Gratz K.F., Pabst R. Effects of autotransplanted lymph node fragments on the lymphatic system in the pig model. Breast Cancer Res Treat 2010, 120:59-66.
7. Campisi C. Use of autologous interposition vein graft in management of lymphedema: Preliminary experimental and clinical observations. Lymphology 1991, 24:71-76.
8. Caunt M., Mak J., Liang W.C., et al. Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell 2008, 13:331-342.
9. Chang D.W. Lymphaticovenular bypass for lymphedema management in breast cancer patients: A prospective study. Plast Reconstr Surg 2010, 126:752-758.
10. Chen H.C., O'Brien B.M., Rogers I.W., et al. Lymph node transfer for the treatment of obstructive lymphoedema in the canine model. Br J Plast Surg 1990, 43:578-586.
11. Clark B., Sitzia J., Harlow W. Incidence and risk of arm oedema following treatment for breast cancer: A three-year follow-up study. QJM 2005, 98:343-348.
12. Enholm B., Paavonen K., Ristimaki A., et al. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene 1997, 14:2475-2483.
13. Ferrara N., Mass R.D., Campa C., Kim R. Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu Rev Med 2007, 58:491-504.
14. Ferrell R.E., Finegold D.N. Research perspectives in inherited lymphatic disease: An update. Ann N Y Acad Sci 2008, 1131:134-139.
15. Fu K., Izquierdo R., Vandevender D., et al. Transplantation of lymph node fragments in a rabbit ear lymphedema model: A new method for restoring the lymphatic pathway. Plast Reconstr Surg 1998, 101:134-141.
16. Hadamitzky C., Blum K.S., Pabst R. Regeneration of autotransplanted avascular lymph nodes in the rat is improved by platelet-rich plasma. J Vasc Res 2009, 46:389-396.
17. Holopainen T., Bry M., Alitalo K., Saaristo A. Perspectives on lymphangiogenesis and angiogenesis in cancer. J Surg Oncol 2011, 103:484-488.
18. Iozzo R.V., San Antonio J.D. Heparan sulfate proteoglycans: Heavy hitters in the angiogenesis arena. J Clin Invest 2001, 108:349-355.
19. Joukov V., Sorsa T., Kumar V., et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J 1997, 16:3898-3911.
20. Karkkainen M.J., Saaristo A., Jussila L., et al. A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci USA 2001, 98:12677-12682.
21. Karpanen T., Bry M., Ollila H.M., et al. Overexpression of vascular endothelial growth factor-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy. Circ Res 2008, 103:1018-1026.
22. Kerbel R., Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002, 2:727-739.
23. Lahteenvuo M., Honkonen K., Tervala T., et al. Growth factor therapy and autologous lymph node transfer in lymphedema. Circulation 2011, 123:613-620.
24. Lin C.H., Ali R., Chen S.C., et al. Vascularized groin lymph node transfer using the wrist as a recipient site for management of postmastectomy upper extremity lymphedema. Plast Reconstr Surg 2009, 123:1265-1275.
25. Lohela M., Bry M., Tammela T., Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009, 21:154-165.
26. McLaughlin S.A., Wright M.J., Morris K.T., et al. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: Patient perceptions and precautionary behaviors. J Clin Oncol 2008, 26:5220-5226.
27. Mebius R.E., Streeter P.R., Breve J., et al. The influence of afferent lymphatic vessel interruption on vascular addressin expression. J Cell Biol 1991, 115:85-95.
28. Oliver G. Lymphatic vasculature development. Nat Rev Immunol 2004, 4:35-45.
29. Olsson A.K., Dimberg A., Kreuger J., et al. VEGF receptor signalling-In control of vascular function. Nat Rev Mol Cell Biol 2006, 7:359-371.
30. Rabson J.A., Geyer S.J., Levine G., et al. Tumor immunity in rat lymph nodes following transplantation. Ann Surg 1982, 196:92-99.
31. Rissanen T.T., Markkanen J.E., Gruchala M., et al. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res 2003, 92:1098-1106.
32. Rockson S.G. Lymphedema. Am J Med 2001, 110:288-295.
33. Saaristo A., Veikkola T., Tammela T., et al. Lymphangiogenic gene therapy with minimal blood vascular side effects. J Exp Med 2002, 196:719-730.
34. Saaristo A.M., Niemi T., Viitanen T., et al. Microvascular breast reconstruction and lymph node transfer for postmastectomy lymphedema patients. Ann Surg 2011, (in press).
35. Schaper W. The renaissance of vascular endothelial growth factor, part B. Circ Res 2008, 103:903-904.
36. Sleeman J.P., Thiele W. Tumor metastasis and the lymphatic vasculature. Int J Cancer 2009, 125:2747-2756.
37. Stacker S.A., Stenvers K., Caesar C., et al. Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. J Biol Chem 1999, 274:32127-32136.
38. Suami H., Chang D.W. Overview of surgical treatments for breast cancer-related lymphedema. Plast Reconstr Surg 2010, 126:1853-1863.
39. Szuba A., Cooke J.P., Yousuf S., Rockson S.G. Decongestive lymphatic therapy for patients with cancer-related or primary lymphedema. Am J Med 2000, 109:296-300.
40. Tabibiazar R., Cheung L., Han J., et al. Inflammatory manifestations of experimental lymphatic insufficiency. PLoS Med 2006, 3:e254.
41. Tammela T., Alitalo K. Lymphangiogenesis: Molecular mechanisms and future promise. Cell 2010, 140:460-476.
42. Tammela T., Saaristo A., Holopainen T., et al. Therapeutic differentiation and maturation of lymphatic vessels after lymph node dissection and transplantation. Nat Med 2007, 13:1458-1466.
43. Tobbia D., Semple J., Baker A., et al. Experimental assessment of autologous lymph node transplantation as treatment of postsurgical lymphedema. Plast Reconstr Surg 2009, 124:777-786.
44. Veikkola T., Jussila L., Makinen T., et al. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J 2001, 20:1223-1231.
45. Warren A.G., Brorson H., Borud L.J., Slavin S.A. Lymphedema: A comprehensive review. Ann Plast Surg 2007, 59:464-472.
46. Weiss M., Baumeister R.G., Hahn K. Post-therapeutic lymphedema: Scintigraphy before and after autologous lymph vessel transplantation: 8 years of long-term follow-up. Clin Nucl Med 2002, 27:788-792.
47. Wirzenius M., Tammela T., Uutela M., et al. Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting. J Exp Med 2007, 204:1431-1440.
48. Yoon Y.S., Murayama T., Gravereaux E., et al. VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema. J Clin Invest 2003, 111:717-725.